Target (CBDY) Liabilities and Shareholders Equity (2013 - 2026)
Target (CBDY) reported Liabilities and Shareholders Equity of $6.1 million for Q1 2026, down 8.91% year-over-year from $6.7 million in Q1 2025, and down 1.63% quarter-over-quarter from $6.2 million in Q4 2025.
Target (CBDY) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Target (CBDY) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $6.1 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $6.1 million, down 8.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.0 million (down 15.88% YoY), and the FY2025 annual result was $6.2 million, down 18.44% from the prior year.
- Liabilities and Shareholders Equity retreated to $6.1 million in Q1 2026 per CBDY's latest filing, from $6.2 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $10.6 million in Q3 2022 and troughed at $6.1 million in Q1 2026.
- A 5-year average of $7.6 million and a median of $7.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- On a YoY basis, Liabilities and Shareholders Equity climbed as much as 16.86% in 2023 and fell as far as 21.46% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $7.6 million in 2022, then increased by 16.86% to $8.8 million in 2023, then retreated by 14.34% to $7.6 million in 2024, then declined by 18.44% to $6.2 million in 2025, then slipped by 1.63% to $6.1 million in 2026.
- Business Quant data shows CBDY's Liabilities and Shareholders Equity at $6.1 million in Q1 2026, $6.2 million in Q4 2025, and $6.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Target | - | - | 191,787.00 | 6.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.08 Mn |
| Dec 31, 2025 | 6.18 Mn |
| Sep 30, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.59 Mn |
| Mar 31, 2025 | 6.67 Mn |
| Dec 31, 2024 | 7.57 Mn |
| Sep 30, 2024 | 7.59 Mn |
| Jun 30, 2024 | 7.94 Mn |
| Mar 31, 2024 | 7.07 Mn |
| Dec 31, 2023 | 8.84 Mn |
| Sep 30, 2023 | 8.33 Mn |
| Jun 30, 2023 | 9.02 Mn |
| Mar 31, 2023 | 7.69 Mn |
| Dec 31, 2022 | 7.57 Mn |
| Sep 30, 2022 | 10.60 Mn |
| Jun 30, 2021 | 13.58 Mn |
| Mar 31, 2021 | 13.89 Mn |
| Dec 31, 2020 | 13.04 Mn |
| Sep 30, 2020 | 17.25 Mn |
| Jun 30, 2020 | 15.81 Mn |